Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection
AbstractThe aim of this study was to determine the efficacy of hepatitis B virus [HBV] vaccination and the response to vaccine in individuals on haemodialysis with and without HCV infection. From April 2000 to September 2003 all haemodialysis patients referred to the haemodialysis department in a Babol hospital received 4 microg vaccine intramuscularly at 0, 1, and 6 months. All were negative for HBV infection markers [HBcAb, HBsAg and HBsAb]. Of 62 patients, 53 [85.5%] responded to vaccination and 26 [49.1%] were high responders. All individuals with HCV infection responded to vaccination. Duration of haemodialysis had no effect on response to vaccination
Sorkhi, H., Roushan, M.R.H., Al Hashemi, G.H., Dooki, M.R.E. & Bai, S. (2008). Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection. http://www.who.int/iris/handle/10665/117496
EMHJ - Eastern Mediterranean Health Journal, 14 (4), 798-803, 2008
MetadataShow full item record
Showing items related by title and MeSH subject.
A collaborative study of the proposed international reference preparation for hepatitis B vaccine containing plasma-derived hepatitis B surface antigen (HBsAg / by Morag Ferguson, Valerie Seagroat and Geoffrey C. Schild Ferguson, Morag; Seagroatt, Valerie; Schild, Geoffrey Christopher; World Health Organization. Biologicals Unit (WHO/BS/86.1525, Rev.1. Unpublished, 1986)